Ole Wichmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8307865/publications.pdf

Version: 2024-02-01

105 4,738 37 64
papers citations h-index g-index

118 118 118 5984 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study. European Journal of Health Economics, 2022, 23, 67-80.	1.4	6
2	Risk of Guillain–Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 January 2000 to 4 April 2020. Eurosurveillance, 2022, 27, .	3.9	2
3	Tick-Borne Encephalitis Risk Increases with Dog Ownership, Frequent Walks, and Gardening: A Case-Control Study in Germany 2018–2020. Microorganisms, 2022, 10, 690.	1.6	6
4	Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany. Scientific Reports, 2022, 12 , .	1.6	17
5	Monitoring influenza vaccination coverage and acceptance among health-care workers in German hospitals – results from three seasons. Human Vaccines and Immunotherapeutics, 2021, 17, 664-672.	1.4	12
6	Determinants of physician attitudes towards the new selective measles vaccine mandate in Germany. BMC Public Health, 2021, 21, 566.	1.2	19
7	Using existing systematic reviews for developing vaccination recommendations: Results of an international expert workshop. Vaccine, 2021, 39, 3103-3110.	1.7	2
8	Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value in Health, 2021, 24, 32-40.	0.1	10
9	Invasive Haemophilus influenzae Infections in Germany After the Introduction of Routine Childhood Immunization, 2001–2016. Open Forum Infectious Diseases, 2020, 7, ofaa444.	0.4	10
10	Barriers and drivers to adult vaccination among family physicians – Insights for tailoring the immunization program in Germany. Vaccine, 2020, 38, 4252-4262.	1.7	56
11	Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany — Results from a nationwide population-based survey. International Journal of Infectious Diseases, 2019, 83, 3-11.	1.5	13
12	Epidemiology and cost of seasonal influenza in Germany - a claims data analysis. BMC Public Health, 2019, 19, 1090.	1.2	25
13	Influenza and pertussis vaccination during pregnancy – attitudes, practices and barriers in gynaecological practices in Germany. BMC Health Services Research, 2019, 19, 616.	0.9	26
14	Epidemiology of Tick-Borne Encephalitis (TBE) in Germany, 2001–2018. Pathogens, 2019, 8, 42.	1.2	49
15	A probable case of tick-borne encephalitis (TBE) acquired in England, July 2019. Eurosurveillance, 2019, 24, .	3.9	29
16	Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany – a mathematical modelling study. BMC Medicine, 2018, 16, 3.	2.3	18
17	How baby's first shot determines the development of maternal attitudes towards vaccination. Vaccine, 2018, 36, 3018-3026.	1.7	20
18	Impfpräention in Deutschland: Ein Überblick zu den Entwicklungen der letzten 25 Jahren. Public Health Forum, 2018, 26, 260-265.	0.1	2

#	Article	IF	Citations
19	Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Medicine, 2018, 16, 110.	2.3	106
20	Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60+. BMC Public Health, 2018, 18, 885.	1.2	28
21	Factors associated with parental acceptance of seasonal influenza vaccination for their children – A telephone survey in the adult population in Germany. Vaccine, 2017, 35, 3789-3796.	1.7	22
22	Is the impact of childhood influenza vaccination less than expected: a transmission modelling study. BMC Infectious Diseases, 2017, 17, 258.	1.3	23
23	Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infectious Diseases, 2017, 17, 356.	1.3	21
24	Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0169368.	1.1	166
25	Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 2017, 15, 18.	0.6	24
26	Risk of Intussusception After Rotavirus Vaccination. Deutsches Ärzteblatt International, 2017, 114, 255-262.	0.6	32
27	Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Eurosurveillance, 2017, 22, .	3.9	30
28	Risk of Invasive Meningococcal Disease in Men Who Have Sex with Men: Lessons Learned from an Outbreak in Germany, 2012—2013. PLoS ONE, 2016, 11, e0160126.	1.1	20
29	Use of existing systematic reviews for evidence assessments in infectious disease prevention: a comparative case study. Systematic Reviews, 2016, 5, 171.	2.5	8
30	Implementing efficient and sustainable collaboration between National Immunization Technical Advisory Groups: Report on the 3rd International Technical Meeting, Paris, France, 8–9 December 2014. Vaccine, 2016, 34, 1325-1330.	1.7	8
31	Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero \hat{A}^{\otimes} to reduce meningococcal group B disease in Germany. Vaccine, 2016, 34, 3412-3419.	1.7	33
32	Current and future effects of varicella and herpes zoster vaccination in Germany $\hat{a}\in$ Insights from a mathematical model in a country with universal varicella vaccination. Human Vaccines and Immunotherapeutics, 2016, 12, 1-11.	1.4	21
33	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics, 2016, 34, 227-244.	1.7	97
34	Evaluation of a temporary vaccination recommendation in response to an outbreak of invasive meningococcal serogroup C disease in men who have sex with men in Berlin, 2013–2014. Eurosurveillance, 2016, 21, 12-22.	3.9	20
35	Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infectious Diseases, 2015, 15, 429.	1.3	117
36	Skewed risk perceptions in pregnant women: the case of influenza vaccination. BMC Public Health, 2015, 15, 1308.	1.2	28

#	Article	IF	CITATIONS
37	Effectiveness of Routine and Booster Pertussis Vaccination in Children and Adolescents, Federal State of Brandenburg, Germany, 2002–2012. Pediatric Infectious Disease Journal, 2015, 34, 513-519.	1.1	24
38	Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany. BMC Infectious Diseases, 2015, 15, 137.	1.3	15
39	Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study. BMC Public Health, 2015, 15, 618.	1.2	81
40	Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health, 2015, 15, 533.	1.2	40
41	Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011. Human Vaccines and Immunotherapeutics, 2014, 10, 140-145.	1.4	14
42	Knowledge, attitude, and uptake related to human papillomavirus vaccination among young women in Germany recruited via a social media site. Human Vaccines and Immunotherapeutics, 2014, 10, 2527-2535.	1.4	33
43	Measles incidence and reporting trends in Germany, 2007–2011. Bulletin of the World Health Organization, 2014, 92, 742-749.	1.5	22
44	Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination. Vaccine, 2014, 32, 6349-6355.	1.7	9
45	Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Medicine, 2014, 12, 244.	2.3	42
46	Vaccination coverage among children in Germany estimated by analysis of health insurance claims data. Human Vaccines and Immunotherapeutics, 2014, 10, 476-484.	1.4	59
47	Cost-effectiveness of childhood rotavirus vaccination in Germany. Vaccine, 2014, 32, 1964-1974.	1.7	23
48	Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25Âyear-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infectious Diseases, 2014, 14, 87.	1.3	50
49	Bayesian parameter inference for dynamic infectious disease modelling: rotavirus in Germany. Statistics in Medicine, 2014, 33, 1580-1599.	0.8	15
50	Evidence-based decision-making in infectious diseases epidemiology, prevention and control: matching research questions to study designs and quality appraisal tools. BMC Medical Research Methodology, 2014, 14, 69.	1.4	23
51	Methodological quality of systematic reviews on influenza vaccination. Vaccine, 2014, 32, 1678-1684.	1.7	33
52	Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine, 2014, 32, 5564-5569.	1.7	32
53	Modelling the epidemiological impact of rotavirus vaccination in Germany – A Bayesian approach. Vaccine, 2014, 32, 5250-5257.	1.7	16
54	Influenza vaccination in HIV-infected individuals: Systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine, 2014, 32, 5585-5592.	1.7	44

#	Article	IF	CITATIONS
55	Cross-sectional study on factors associated with influenza vaccine uptake and pertussis vaccination status among pregnant women in Germany. Vaccine, 2014, 32, 4131-4139.	1.7	85
56	The Efficacy and Duration of Vaccine Protection Against Human Papillomavirus. Deutsches Ärzteblatt International, 2014, 111, 584-91.	0.6	39
57	Knowledge, attitude, and uptake related to human papillomavirus vaccination among young women in Germany recruited via a social media site. Human Vaccines and Immunotherapeutics, 2014, 10, .	1.4	1
58	Neurological complications of dengue virus infection. Lancet Neurology, The, 2013, 12, 906-919.	4.9	351
59	Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. European Journal of Health Economics, 2013, 14, 1015-1026.	1.4	65
60	Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Services Research, 2013, 13, 359.	0.9	31
61	Epidemiology of invasive meningococcal disease inÂGermany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine. Journal of Infection, 2013, 66, 48-56.	1.7	34
62	Will Dengue Vaccines Be Used in the Public Sector and if so, How? Findings from an 8-country Survey of Policymakers and Opinion Leaders. PLoS Neglected Tropical Diseases, 2013, 7, e2127.	1.3	24
63	Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010. Human Vaccines and Immunotherapeutics, 2013, 9, 74-82.	1.4	37
64	HPV vaccination coverage among women aged $18\hat{a}\in$ 20 years in Germany three years after recommendation of HPV vaccination for adolescent girls. Human Vaccines and Immunotherapeutics, 2013, 9, 1706-1711.	1.4	21
65	Rotavirus Vaccine Effectiveness and Case-control Study on Risk Factors for Breakthrough Infections in Germany, 2010–2011. Pediatric Infectious Disease Journal, 2013, 32, e82-e89.	1.1	55
66	Risk Factors for Cervical Human Papillomavirus Infection and High-Grade Intraepithelial Lesion in Women Aged 20 to 31 Years in Germany. International Journal of Gynecological Cancer, 2013, 23, 519-526.	1.2	30
67	Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Human Vaccines and Immunotherapeutics, 2012, 8, 1407-1415.	1.4	30
68	Prospective hospital-based caseâ€"control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009â€"2010 using matched hospital and test-negative controls. BMC Infectious Diseases, 2012, 12, 127.	1.3	18
69	Lessons from a one-year hospital-based surveillance of acute respiratory infections in Berlin-comparing case definitions to monitor influenza. BMC Public Health, 2012, 12, 245.	1.2	10
70	Barriers to pandemic influenza vaccination and uptake of seasonal influenza vaccine in the post-pandemic season in Germany. BMC Public Health, 2012, 12, 938.	1.2	64
71	Effectiveness and Timing of Vaccination during School Measles Outbreak. Emerging Infectious Diseases, 2012, 18, 1405-1413.	2.0	15
72	Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 – Results from thirteen consecutive cross-sectional surveys. Vaccine, 2011, 29, 4008-4012.	1.7	48

#	Article	IF	CITATIONS
73	Seasonal influenza vaccine uptake in Germany 2007/2008 and 2008/2009: Results from a national health update survey. Vaccine, 2011, 29, 4492-4498.	1.7	40
74	Effectiveness of the ASO3-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10. PLoS ONE, 2011, 6, e19932.	1.1	12
75	Molecular Surveillance of Circulating Dengue Genotypes Through European Travelers. Journal of Travel Medicine, 2011, 18, 183-190.	1.4	36
76	Herpes zoster in Germany: Quantifying the burden of disease. BMC Infectious Diseases, 2011, 11, 173.	1.3	100
77	Determinants of tetanus and seasonal influenza vaccine uptake in adults living in Germany. Hum Vaccin, 2011, 7, 1317-1325.	2.4	55
78	Closer to the Goal: Efforts in Measles Elimination in Germany 2010. Journal of Infectious Diseases, 2011, 204, S373-S380.	1.9	27
79	Reply letter. Hum Vaccin, 2011, 7, 131-131.	2.4	0
80	Health Economics of Dengue: A Systematic Literature Review and Expert Panel's Assessment. American Journal of Tropical Medicine and Hygiene, 2011, 84, 473-488.	0.6	140
81	Dengue in Thailand and Cambodia: An Assessment of the Degree of Underrecognized Disease Burden Based on Reported Cases. PLoS Neglected Tropical Diseases, 2011, 5, e996.	1.3	88
82	Communicable Diseases Prioritized for Surveillance and Epidemiological Research: Results of a Standardized Prioritization Procedure in Germany, 2011. PLoS ONE, 2011, 6, e25691.	1.1	98
83	Estimation of measles vaccine efficacy and critical vaccination coverage in a highly vaccinated population. Journal of the Royal Society Interface, 2010, 7, 1537-1544.	1.5	59
84	Dengue Incidence in Urban and Rural Cambodia: Results from Population-Based Active Fever Surveillance, 2006–2008. PLoS Neglected Tropical Diseases, 2010, 4, e903.	1.3	91
85	Forecasting dengue vaccine demand in disease endemic and non-endemic countries. Hum Vaccin, 2010, 6, 745-753.	2.4	29
86	Potential dengue vaccine demand in disease endemic and non-endemic countries. Procedia in Vaccinology, 2010, 2, 113-117.	0.4	0
87	Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study. BMC Public Health, 2009, 9, 155.	1.2	48
88	Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagnostic Microbiology and Infectious Disease, 2009, 65, 42-48.	0.8	24
89	furter efforts needed to achieve measles elimination in Germany: results of an outbreak investigation. Bulletin of the World Health Organization, 2009, 87, 108-115.	1.5	74
90	Determinants of Malaria Prophylaxis Among German Travelers to Kenya, Senegal, and Thailand. Journal of Travel Medicine, 2008, 15, 162-171.	1.4	44

#	Article	IF	CITATIONS
91	Seroprevalence study of <i>Francisella tularensis </i> among hunters in Germany. FEMS Immunology and Medical Microbiology, 2008, 53, 183-189.	2.7	48
92	Phylogenetic and Caseâ€Control Study on Hepatitis E Virus Infection in Germany. Journal of Infectious Diseases, 2008, 198, 1732-1741.	1.9	262
93	Antibodies against <i>Rickettsia</i> spp. in Hunters, Germany. Emerging Infectious Diseases, 2008, 14, 1961-1963.	2.0	15
94	Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators. Journal of Infectious Diseases, 2007, 195, 1089-1096.	1.9	140
95	Large Measles Outbreak at a German Public School, 2006. Pediatric Infectious Disease Journal, 2007, 26, 782-786.	1.1	65
96	High residual chloroquine blood levels in African children with severe malaria seeking healthcare. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 637-642.	0.7	6
97	Clinical features and pitfalls in the laboratory diagnosis of dengue in travellers. BMC Infectious Diseases, 2006, 6, 120.	1.3	31
98	Dengue in Travelers: a Review. Journal of Travel Medicine, 2006, 11, 161-170.	1.4	29
99	Dengue Antibody Prevalence in German Travelers. Emerging Infectious Diseases, 2005, 11, 762-765.	2.0	30
100	Reply to Meshnick and Trumpower. Journal of Infectious Diseases, 2005, 191, 822-823.	1.9	0
101	Risk and Spectrum of Diseases in Travelers to Popular Tourist Destinations. Journal of Travel Medicine, 2005, 12, 248-253.	1.4	108
102	Screening for Mutations Related to Atovaquone/Proguanil Resistance in Treatment Failures and Other Imported Isolates of Plasmodium falciparumin Europe. Journal of Infectious Diseases, 2004, 190, 1541-1546.	1.9	73
103	Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Tropical Medicine and International Health, 2004, 9, 1022-1029.	1.0	185
104	Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malaria Journal, 2004, 3, 14.	0.8	54
105	Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malaria Journal, 2003, 2, 17.	0.8	18